ID   UBP5_HUMAN              Reviewed;         858 AA.
AC   P45974; D3DUS7; D3DUS8; Q96J22;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-1996, sequence version 2.
DT   15-MAR-2017, entry version 177.
DE   RecName: Full=Ubiquitin carboxyl-terminal hydrolase 5;
DE            EC=3.4.19.12;
DE   AltName: Full=Deubiquitinating enzyme 5;
DE   AltName: Full=Isopeptidase T;
DE   AltName: Full=Ubiquitin thioesterase 5;
DE   AltName: Full=Ubiquitin-specific-processing protease 5;
GN   Name=USP5; Synonyms=ISOT;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PARTIAL PROTEIN SEQUENCE.
RX   PubMed=7498549; DOI=10.1016/0014-5793(95)01287-7;
RA   Falquet L., Paquet N., Frutiger S., Hughes G.J., Hoang-Van K.,
RA   Jaton J.-C.;
RT   "cDNA cloning of a human 100 kDa de-ubiquitinating enzyme: the 100 kDa
RT   human de-ubiquitinase belongs to the ubiquitin C-terminal hydrolase
RT   family 2 (UCH2).";
RL   FEBS Lett. 376:233-237(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA].
RX   PubMed=8723724; DOI=10.1101/gr.6.4.314;
RA   Ansari-Lari M.A., Muzny D.M., Lu J., Lu F., Lilley C.E., Spanos S.,
RA   Malley T., Gibbs R.A.;
RT   "A gene-rich cluster between the CD4 and triosephosphate isomerase
RT   genes at human chromosome 12p13.";
RL   Genome Res. 6:314-326(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=9074930; DOI=10.1101/gr.7.3.268;
RA   Ansari-Lari M.A., Shen Y., Muzny D.M., Lee W., Gibbs R.A.;
RT   "Large-scale sequencing in human chromosome 12p13: experimental and
RT   computational gene structure determination.";
RL   Genome Res. 7:268-280(1997).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RA   Tashayev V.L., O'Connor L.B., Larsen C.N., Kasperek E., Pickart C.M.;
RL   Submitted (NOV-1995) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS LONG AND SHORT).
RC   TISSUE=Kidney, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   CHARACTERIZATION.
RX   PubMed=7851534; DOI=10.1016/0014-5793(94)01451-6;
RA   Falquet L., Paquet N., Frutiger S., Hughes G.J., Hoang-Van K.,
RA   Jaton J.-C.;
RT   "A human de-ubiquitinating enzyme with both isopeptidase and peptidase
RT   activities in vitro.";
RL   FEBS Lett. 359:73-77(1995).
RN   [8]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [9]
RP   MUTAGENESIS OF ARG-221; CYS-335; ASP-435; MET-666 AND MET-734, AND
RP   POLYUBIQUITIN BINDING.
RX   PubMed=18482987; DOI=10.1074/jbc.M800947200;
RA   Reyes-Turcu F.E., Shanks J.R., Komander D., Wilkinson K.D.;
RT   "Recognition of polyubiquitin isoforms by the multiple ubiquitin
RT   binding modules of isopeptidase T.";
RL   J. Biol. Chem. 283:19581-19592(2008).
RN   [10]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [11]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [12]
RP   FUNCTION.
RX   PubMed=19098288; DOI=10.1074/jbc.M805871200;
RA   Dayal S., Sparks A., Jacob J., Allende-Vega N., Lane D.P.,
RA   Saville M.K.;
RT   "Suppression of the deubiquitinating enzyme USP5 causes the
RT   accumulation of unanchored polyubiquitin and the activation of p53.";
RL   J. Biol. Chem. 284:5030-5041(2009).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-783, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-783, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   MUTAGENESIS OF 221-ARG--TYR-223 AND TYR-261.
RX   PubMed=22216260; DOI=10.1371/journal.pone.0029362;
RA   Zhang Y.H., Zhou C.J., Zhou Z.R., Song A.X., Hu H.Y.;
RT   "Domain analysis reveals that a deubiquitinating enzyme USP13 performs
RT   non-activating catalysis for Lys63-linked polyubiquitin.";
RL   PLoS ONE 6:E29362-E29362(2011).
RN   [17]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [18]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E.,
RA   Timmerman E., Prieto J., Arnesen T., Sherman F., Gevaert K.,
RA   Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-
RT   terminal acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-292; SER-779; SER-783
RP   AND SER-785, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-156, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.09 ANGSTROMS) OF 163-291 IN COMPLEX WITH
RP   UBIQUITIN, ZINC-BINDING, AND MUTAGENESIS OF CYS-199; CYS-202; CYS-219
RP   AND HIS-232.
RX   PubMed=16564012; DOI=10.1016/j.cell.2006.02.038;
RA   Reyes-Turcu F.E., Horton J.R., Mullally J.E., Heroux A., Cheng X.,
RA   Wilkinson K.D.;
RT   "The ubiquitin binding domain ZnF UBP recognizes the C-terminal
RT   diglycine motif of unanchored ubiquitin.";
RL   Cell 124:1197-1208(2006).
RN   [22]
RP   STRUCTURE BY NMR OF 655-772.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the first and second UBA domains in the human
RT   ubiquitin specific protease 5 (isopeptidase 5).";
RL   Submitted (JUN-2006) to the PDB data bank.
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 1-858 IN COMPLEX WITH
RP   UBIQUITIN, DISULFIDE BOND, AND ZINC-BINDING.
RA   Walker J.R., Avvakumov G.V., Xue S., Butler-Cole C., Weigelt J.,
RA   Bountra C., Arrowsmith C.H., Edwards A.M., Bochkarev A.,
RA   Dhe-Paganon S.;
RT   "Covalent ubiquitin-USP5 complex.";
RL   Submitted (DEC-2009) to the PDB data bank.
CC   -!- FUNCTION: Cleaves linear and branched multiubiquitin polymers with
CC       a marked preference for branched polymers. Involved in unanchored
CC       'Lys-48'-linked polyubiquitin disassembly. Binds linear and 'Lys-
CC       63'-linked polyubiquitin with a lower affinity. Knock-down of USP5
CC       causes the accumulation of p53/TP53 and an increase in p53/TP53
CC       transcriptional activity because the unanchored polyubiquitin that
CC       accumulates is able to compete with ubiquitinated p53/TP53 but not
CC       with MDM2 for proteasomal recognition.
CC       {ECO:0000269|PubMed:19098288}.
CC   -!- CATALYTIC ACTIVITY: Thiol-dependent hydrolysis of ester,
CC       thioester, amide, peptide and isopeptide bonds formed by the C-
CC       terminal Gly of ubiquitin (a 76-residue protein attached to
CC       proteins as an intracellular targeting signal).
CC   -!- SUBUNIT: Interacts with TRIML1. {ECO:0000250}.
CC   -!- INTERACTION:
CC       Q15038:DAZAP2; NbExp=3; IntAct=EBI-741277, EBI-724310;
CC       P54727:RAD23B; NbExp=2; IntAct=EBI-741277, EBI-954531;
CC       O75528:TADA3; NbExp=2; IntAct=EBI-741277, EBI-473249;
CC       Q8WW34:TMEM239; NbExp=3; IntAct=EBI-741277, EBI-9675724;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Long;
CC         IsoId=P45974-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=P45974-2; Sequence=VSP_005259;
CC   -!- DOMAIN: The UBP-type zinc finger domain interacts selectively with
CC       an unmodified C-terminus of the proximal ubiquitin. Both UBA
CC       domains are involved in polyubiquitin recognition.
CC   -!- MISCELLANEOUS: The UBP-type zinc finger domain crystallizes as a
CC       dimer linked by a disulfide bond between the Cys-195 residues of
CC       both molecules, but there is no evidence that the full-length USP5
CC       exists as a dimer.
CC   -!- SIMILARITY: Belongs to the peptidase C19 family. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X91349; CAA62690.1; -; mRNA.
DR   EMBL; U47927; AAC50465.1; -; mRNA.
DR   EMBL; U47924; AAB51314.1; -; Genomic_DNA.
DR   EMBL; U47924; AAB51315.1; -; Genomic_DNA.
DR   EMBL; U35116; AAA78934.1; -; mRNA.
DR   EMBL; CH471116; EAW88724.1; -; Genomic_DNA.
DR   EMBL; CH471116; EAW88725.1; -; Genomic_DNA.
DR   EMBL; CH471116; EAW88726.1; -; Genomic_DNA.
DR   EMBL; CH471116; EAW88727.1; -; Genomic_DNA.
DR   EMBL; BC004889; AAH04889.1; -; mRNA.
DR   EMBL; BC005139; AAH05139.1; -; mRNA.
DR   CCDS; CCDS31733.1; -. [P45974-2]
DR   CCDS; CCDS41743.1; -. [P45974-1]
DR   PIR; S68227; S68227.
DR   RefSeq; NP_001092006.1; NM_001098536.1. [P45974-1]
DR   RefSeq; NP_003472.2; NM_003481.2. [P45974-2]
DR   UniGene; Hs.631661; -.
DR   PDB; 2DAG; NMR; -; A=655-715.
DR   PDB; 2DAK; NMR; -; A=723-772.
DR   PDB; 2G43; X-ray; 2.09 A; A/B=163-291.
DR   PDB; 2G45; X-ray; 1.99 A; A/D=163-291.
DR   PDB; 3IHP; X-ray; 2.80 A; A/B=1-858.
DR   PDBsum; 2DAG; -.
DR   PDBsum; 2DAK; -.
DR   PDBsum; 2G43; -.
DR   PDBsum; 2G45; -.
DR   PDBsum; 3IHP; -.
DR   ProteinModelPortal; P45974; -.
DR   SMR; P45974; -.
DR   BioGrid; 113751; 79.
DR   DIP; DIP-34459N; -.
DR   IntAct; P45974; 11.
DR   MINT; MINT-5001006; -.
DR   STRING; 9606.ENSP00000229268; -.
DR   BindingDB; P45974; -.
DR   ChEMBL; CHEMBL6158; -.
DR   GuidetoPHARMACOLOGY; 2431; -.
DR   MEROPS; C19.001; -.
DR   iPTMnet; P45974; -.
DR   PhosphoSitePlus; P45974; -.
DR   SwissPalm; P45974; -.
DR   BioMuta; USP5; -.
DR   DMDM; 1717869; -.
DR   REPRODUCTION-2DPAGE; IPI00375145; -.
DR   EPD; P45974; -.
DR   MaxQB; P45974; -.
DR   PaxDb; P45974; -.
DR   PeptideAtlas; P45974; -.
DR   PRIDE; P45974; -.
DR   DNASU; 8078; -.
DR   Ensembl; ENST00000229268; ENSP00000229268; ENSG00000111667. [P45974-1]
DR   Ensembl; ENST00000389231; ENSP00000373883; ENSG00000111667. [P45974-2]
DR   GeneID; 8078; -.
DR   KEGG; hsa:8078; -.
DR   UCSC; uc001qrh.5; human. [P45974-1]
DR   CTD; 8078; -.
DR   DisGeNET; 8078; -.
DR   GeneCards; USP5; -.
DR   HGNC; HGNC:12628; USP5.
DR   HPA; HPA006756; -.
DR   MIM; 601447; gene.
DR   neXtProt; NX_P45974; -.
DR   OpenTargets; ENSG00000111667; -.
DR   PharmGKB; PA37253; -.
DR   eggNOG; KOG0944; Eukaryota.
DR   eggNOG; COG5207; LUCA.
DR   GeneTree; ENSGT00390000000874; -.
DR   HOGENOM; HOG000162311; -.
DR   HOVERGEN; HBG002833; -.
DR   InParanoid; P45974; -.
DR   KO; K11836; -.
DR   OMA; GQRAYLH; -.
DR   OrthoDB; EOG091G01W3; -.
DR   PhylomeDB; P45974; -.
DR   TreeFam; TF300576; -.
DR   BRENDA; 3.4.19.12; 2681.
DR   Reactome; R-HSA-5689880; Ub-specific processing proteases.
DR   Reactome; R-HSA-8866652; Synthesis of active ubiquitin: roles of E1 and E2 enzymes.
DR   ChiTaRS; USP5; human.
DR   EvolutionaryTrace; P45974; -.
DR   GeneWiki; USP5; -.
DR   GenomeRNAi; 8078; -.
DR   PMAP-CutDB; P45974; -.
DR   PRO; PR:P45974; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000111667; -.
DR   CleanEx; HS_USP5; -.
DR   ExpressionAtlas; P45974; baseline and differential.
DR   Genevisible; P45974; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005764; C:lysosome; TAS:ProtInc.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; TAS:ProtInc.
DR   GO; GO:0004843; F:thiol-dependent ubiquitin-specific protease activity; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0036459; F:thiol-dependent ubiquitinyl hydrolase activity; TAS:Reactome.
DR   GO; GO:0043130; F:ubiquitin binding; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0008270; F:zinc ion binding; IEA:InterPro.
DR   GO; GO:0032436; P:positive regulation of proteasomal ubiquitin-dependent protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0016579; P:protein deubiquitination; IDA:ParkinsonsUK-UCL.
DR   GO; GO:0071108; P:protein K48-linked deubiquitination; IMP:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; TAS:Reactome.
DR   GO; GO:0006511; P:ubiquitin-dependent protein catabolic process; IEA:InterPro.
DR   Gene3D; 3.30.40.10; -; 1.
DR   InterPro; IPR001394; Peptidase_C19_UCH.
DR   InterPro; IPR015940; UBA.
DR   InterPro; IPR009060; UBA-like.
DR   InterPro; IPR016652; Ubiquitinyl_hydrolase.
DR   InterPro; IPR018200; USP_CS.
DR   InterPro; IPR028889; USP_dom.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR001607; Znf_UBP.
DR   Pfam; PF00627; UBA; 2.
DR   Pfam; PF00443; UCH; 1.
DR   Pfam; PF02148; zf-UBP; 1.
DR   PIRSF; PIRSF016308; UBP; 1.
DR   SMART; SM00165; UBA; 2.
DR   SMART; SM00290; ZnF_UBP; 1.
DR   SUPFAM; SSF46934; SSF46934; 1.
DR   PROSITE; PS50030; UBA; 2.
DR   PROSITE; PS00972; USP_1; 1.
DR   PROSITE; PS00973; USP_2; 1.
DR   PROSITE; PS50235; USP_3; 1.
DR   PROSITE; PS50271; ZF_UBP; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; Complete proteome;
KW   Direct protein sequencing; Disulfide bond; Hydrolase; Metal-binding;
KW   Phosphoprotein; Protease; Reference proteome; Repeat; Thiol protease;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378}.
FT   CHAIN         2    858       Ubiquitin carboxyl-terminal hydrolase 5.
FT                                /FTId=PRO_0000080623.
FT   DOMAIN      326    856       USP.
FT   DOMAIN      654    695       UBA 1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00212}.
FT   DOMAIN      722    762       UBA 2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00212}.
FT   ZN_FING     197    269       UBP-type. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00502}.
FT   REGION      221    224       Substrate binding.
FT   ACT_SITE    335    335       Nucleophile.
FT   ACT_SITE    818    818       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU10092, ECO:0000255|PROSITE-
FT                                ProRule:PRU10093}.
FT   METAL       199    199       Zinc.
FT   METAL       202    202       Zinc.
FT   METAL       219    219       Zinc.
FT   METAL       232    232       Zinc.
FT   BINDING     209    209       Substrate.
FT   BINDING     259    259       Substrate.
FT   BINDING     261    261       Substrate; via carbonyl oxygen.
FT   BINDING     264    264       Substrate.
FT   MOD_RES       2      2       N-acetylalanine.
FT                                {ECO:0000244|PubMed:19413330,
FT                                ECO:0000244|PubMed:22223895,
FT                                ECO:0000244|PubMed:22814378}.
FT   MOD_RES     156    156       Phosphoserine.
FT                                {ECO:0000244|PubMed:24275569}.
FT   MOD_RES     292    292       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     623    623       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P56399}.
FT   MOD_RES     779    779       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     783    783       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     785    785       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   DISULFID    195    816       {ECO:0000269|Ref.23}.
FT   VAR_SEQ     629    652       GSLGFYGNEDEDSFCSPHFSSPTS -> A (in isoform
FT                                Short). {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_005259.
FT   MUTAGEN     199    199       C->A: Decreased rate of activity and
FT                                decreased zinc binding.
FT                                {ECO:0000269|PubMed:16564012}.
FT   MUTAGEN     202    202       C->A: Decreased rate of activity.
FT                                {ECO:0000269|PubMed:16564012}.
FT   MUTAGEN     219    219       C->A: Decreased rate of activity.
FT                                {ECO:0000269|PubMed:16564012}.
FT   MUTAGEN     221    223       RRY->KWF: Loss of polyubiquitin binding
FT                                and subsequent activation.
FT                                {ECO:0000269|PubMed:22216260}.
FT   MUTAGEN     221    221       R->A: Loss of polyubiquitin hydrolysis.
FT                                Loss of ubiquitin binding; when
FT                                associated with A-335.
FT                                {ECO:0000269|PubMed:18482987}.
FT   MUTAGEN     232    232       H->A: Decreased rate of activity.
FT                                {ECO:0000269|PubMed:16564012}.
FT   MUTAGEN     261    261       Y->F: Loss of polyubiquitin binding.
FT                                {ECO:0000269|PubMed:22216260}.
FT   MUTAGEN     335    335       C->A: Loss of activity. Loss of ubiquitin
FT                                binding; when associated with A-221.
FT                                Lower affinity for triubiquitin and
FT                                tetraubiquitin, but no effect on affinity
FT                                for diubiquitin; when associated with E-
FT                                666. Lower affinity for diubiquitin,
FT                                triubiquitin and tetraubiquitin; when
FT                                associated with E-734.
FT                                {ECO:0000269|PubMed:18482987}.
FT   MUTAGEN     435    435       D->A: Loss of polyubiquitin binding and
FT                                hydrolysis.
FT                                {ECO:0000269|PubMed:18482987}.
FT   MUTAGEN     666    666       M->E: Lower affinity for triubiquitin and
FT                                tetraubiquitin, but no effect on affinity
FT                                for diubiquitin; when associated with A-
FT                                335. No effect on activity; when
FT                                associated with E-734.
FT                                {ECO:0000269|PubMed:18482987}.
FT   MUTAGEN     734    734       M->E: Lower affinity for diubiquitin,
FT                                triubiquitin and tetraubiquitin; when
FT                                associated with A-335. No effect on
FT                                activity; when associated with E-666.
FT                                {ECO:0000269|PubMed:18482987}.
FT   CONFLICT      3      4       EL -> DV (in Ref. 1; CAA62690).
FT                                {ECO:0000305}.
FT   CONFLICT     45     45       I -> V (in Ref. 1; CAA62690).
FT                                {ECO:0000305}.
FT   CONFLICT    468    468       K -> R (in Ref. 4; AAA78934).
FT                                {ECO:0000305}.
FT   CONFLICT    681    681       G -> D (in Ref. 4; AAA78934).
FT                                {ECO:0000305}.
FT   HELIX         5     11       {ECO:0000244|PDB:3IHP}.
FT   HELIX        12     15       {ECO:0000244|PDB:3IHP}.
FT   STRAND       31     34       {ECO:0000244|PDB:3IHP}.
FT   STRAND       43     46       {ECO:0000244|PDB:3IHP}.
FT   TURN         47     49       {ECO:0000244|PDB:3IHP}.
FT   TURN         55     57       {ECO:0000244|PDB:3IHP}.
FT   HELIX        58     65       {ECO:0000244|PDB:3IHP}.
FT   STRAND       69     75       {ECO:0000244|PDB:3IHP}.
FT   STRAND      118    124       {ECO:0000244|PDB:3IHP}.
FT   TURN        125    128       {ECO:0000244|PDB:3IHP}.
FT   STRAND      129    131       {ECO:0000244|PDB:3IHP}.
FT   HELIX       141    154       {ECO:0000244|PDB:3IHP}.
FT   TURN        178    182       {ECO:0000244|PDB:2G45}.
FT   STRAND      200    203       {ECO:0000244|PDB:2G45}.
FT   STRAND      206    211       {ECO:0000244|PDB:2G45}.
FT   TURN        212    214       {ECO:0000244|PDB:2G45}.
FT   STRAND      217    219       {ECO:0000244|PDB:2G45}.
FT   HELIX       232    240       {ECO:0000244|PDB:2G45}.
FT   STRAND      244    247       {ECO:0000244|PDB:2G45}.
FT   STRAND      258    260       {ECO:0000244|PDB:2G45}.
FT   TURN        261    264       {ECO:0000244|PDB:2G45}.
FT   STRAND      265    268       {ECO:0000244|PDB:2G45}.
FT   HELIX       272    277       {ECO:0000244|PDB:2G45}.
FT   TURN        278    280       {ECO:0000244|PDB:2G45}.
FT   TURN        283    285       {ECO:0000244|PDB:2G45}.
FT   HELIX       335    344       {ECO:0000244|PDB:3IHP}.
FT   HELIX       348    354       {ECO:0000244|PDB:3IHP}.
FT   TURN        355    357       {ECO:0000244|PDB:3IHP}.
FT   HELIX       358    364       {ECO:0000244|PDB:3IHP}.
FT   HELIX       369    371       {ECO:0000244|PDB:3IHP}.
FT   HELIX       373    385       {ECO:0000244|PDB:3IHP}.
FT   HELIX       415    421       {ECO:0000244|PDB:3IHP}.
FT   TURN        422    424       {ECO:0000244|PDB:3IHP}.
FT   TURN        426    429       {ECO:0000244|PDB:3IHP}.
FT   STRAND      430    432       {ECO:0000244|PDB:3IHP}.
FT   HELIX       436    449       {ECO:0000244|PDB:3IHP}.
FT   HELIX       457    460       {ECO:0000244|PDB:3IHP}.
FT   STRAND      463    471       {ECO:0000244|PDB:3IHP}.
FT   TURN        472    475       {ECO:0000244|PDB:3IHP}.
FT   STRAND      476    489       {ECO:0000244|PDB:3IHP}.
FT   HELIX       493    495       {ECO:0000244|PDB:3IHP}.
FT   HELIX       499    514       {ECO:0000244|PDB:3IHP}.
FT   HELIX       529    537       {ECO:0000244|PDB:3IHP}.
FT   STRAND      540    547       {ECO:0000244|PDB:3IHP}.
FT   TURN        548    551       {ECO:0000244|PDB:3IHP}.
FT   STRAND      552    564       {ECO:0000244|PDB:3IHP}.
FT   STRAND      567    573       {ECO:0000244|PDB:3IHP}.
FT   STRAND      576    578       {ECO:0000244|PDB:3IHP}.
FT   HELIX       580    582       {ECO:0000244|PDB:3IHP}.
FT   STRAND      584    586       {ECO:0000244|PDB:3IHP}.
FT   STRAND      595    598       {ECO:0000244|PDB:3IHP}.
FT   HELIX       600    602       {ECO:0000244|PDB:3IHP}.
FT   HELIX       658    666       {ECO:0000244|PDB:3IHP}.
FT   HELIX       670    679       {ECO:0000244|PDB:3IHP}.
FT   HELIX       685    695       {ECO:0000244|PDB:3IHP}.
FT   HELIX       700    702       {ECO:0000244|PDB:3IHP}.
FT   HELIX       725    732       {ECO:0000244|PDB:3IHP}.
FT   TURN        733    735       {ECO:0000244|PDB:3IHP}.
FT   HELIX       738    747       {ECO:0000244|PDB:3IHP}.
FT   TURN        748    750       {ECO:0000244|PDB:3IHP}.
FT   HELIX       752    770       {ECO:0000244|PDB:3IHP}.
FT   STRAND      799    812       {ECO:0000244|PDB:3IHP}.
FT   STRAND      818    825       {ECO:0000244|PDB:3IHP}.
FT   STRAND      828    833       {ECO:0000244|PDB:3IHP}.
FT   STRAND      836    839       {ECO:0000244|PDB:3IHP}.
FT   STRAND      849    855       {ECO:0000244|PDB:3IHP}.
SQ   SEQUENCE   858 AA;  95786 MW;  E99CB7CDFA682C65 CRC64;
     MAELSEEALL SVLPTIRVPK AGDRVHKDEC AFSFDTPESE GGLYICMNTF LGFGKQYVER
     HFNKTGQRVY LHLRRTRRPK EEDPATGTGD PPRKKPTRLA IGVEGGFDLS EEKFELDEDV
     KIVILPDYLE IARDGLGGLP DIVRDRVTSA VEALLSADSA SRKQEVQAWD GEVRQVSKHA
     FSLKQLDNPA RIPPCGWKCS KCDMRENLWL NLTDGSILCG RRYFDGSGGN NHAVEHYRET
     GYPLAVKLGT ITPDGADVYS YDEDDMVLDP SLAEHLSHFG IDMLKMQKTD KTMTELEIDM
     NQRIGEWELI QESGVPLKPL FGPGYTGIRN LGNSCYLNSV VQVLFSIPDF QRKYVDKLEK
     IFQNAPTDPT QDFSTQVAKL GHGLLSGEYS KPVPESGDGE RVPEQKEVQD GIAPRMFKAL
     IGKGHPEFST NRQQDAQEFF LHLINMVERN CRSSENPNEV FRFLVEEKIK CLATEKVKYT
     QRVDYIMQLP VPMDAALNKE ELLEYEEKKR QAEEEKMALP ELVRAQVPFS SCLEAYGAPE
     QVDDFWSTAL QAKSVAVKTT RFASFPDYLV IQIKKFTFGL DWVPKKLDVS IEMPEELDIS
     QLRGTGLQPG EEELPDIAPP LVTPDEPKGS LGFYGNEDED SFCSPHFSSP TSPMLDESVI
     IQLVEMGFPM DACRKAVYYT GNSGAEAAMN WVMSHMDDPD FANPLILPGS SGPGSTSAAA
     DPPPEDCVTT IVSMGFSRDQ ALKALRATNN SLERAVDWIF SHIDDLDAEA AMDISEGRSA
     ADSISESVPV GPKVRDGPGK YQLFAFISHM GTSTMCGHYV CHIKKEGRWV IYNDQKVCAS
     EKPPKDLGYI YFYQRVAS
//
